Literature DB >> 23001578

Characteristics of vascular supply to uterine leiomyoma: an analysis of digital subtraction angiography imaging in 518 cases.

Chun-Lin Chen1, Yu-Jing Xu, Ping Liu, Jiang-Hong Zhu, Ben Ma, Bei-Lan Zeng, Yan Zhou, Li Wang, Yi-Xin Tang, Chuan-Jia Guo.   

Abstract

OBJECTIVES: To investigate the characteristics of the vascular supply to uterine leiomyomas based on digital subtraction angiography.
METHODS: The feeding artery, vascularity of uterine leiomyoma and visualisation of the ovarian vessel network were studied in 518 patients undergoing uterine artery embolisation (UAE). Mean patient age was 38.97 ± 6.09 years (range, 22-54 years). The types of vascular supply were analysed by the vascular supply to the leimyoma and grades of vascularity by the degree of enhancement of the leimyoma compared with the myometrium.
RESULTS: The blood supply of leiomyomas could not be classified in 3.28 % of patients. Blood was supplied solely by the uterine artery in 88.61 % of leiomyomas, 8.11 % of leiomyomas were partially fed by an ovarian artery, and 0.39 % by it exclusively. Leiomyoma blood supply was classified as unilateral predominant, bilateral balanced, single unilateral uterine artery and single ovarian artery in 36.48, 49.23, 10.62 and 0.39 % of cases respectively. Leiomyoma vascularity was classified as extremely hypervascular (8.69 %), hypervascular (46.14 %), isovascular (33.39 %) and hypovascular (11.78 %).
CONCLUSIONS: Uterine leiomyomas supplied by both uterine arteries and with rich blood flow were seen in approximately 50 % of patients. However, close attention also should be given to the collateral circulation during UAE.

Entities:  

Mesh:

Year:  2012        PMID: 23001578     DOI: 10.1007/s00330-012-2643-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  18 in total

1.  Uterine-artery embolization versus surgery for symptomatic uterine fibroids.

Authors:  Richard D Edwards; Jonathan G Moss; Mary Ann Lumsden; Olivia Wu; Lilian S Murray; Sara Twaddle; Gordon D Murray
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

2.  Leiomyoma volume changes at follow-up after uterine artery embolization: correlation with the initial leiomyoma volume and location.

Authors:  Nagy N N Naguib; Emmanuel Mbalisike; Nour-Eldin A Nour-Eldin; Alexandra Jost; Thomas Lehnert; Hans Ackermann; Thomas J Vogl
Journal:  J Vasc Interv Radiol       Date:  2010-02-09       Impact factor: 3.464

Review 3.  The role of uterine artery embolization in the management of uterine fibroids.

Authors:  Giovanna Tropeano
Journal:  Curr Opin Obstet Gynecol       Date:  2005-08       Impact factor: 1.927

4.  Midterm results of uterine artery embolization using narrow-size calibrated embozene microspheres.

Authors:  Ulrike Stampfl; Boris Radeleff; Christof Sommer; Sibylle Stampfl; Angelika Dahlke; Nadine Bellemann; Hans-Ulrich Kauczor; Goetz M Richter
Journal:  Cardiovasc Intervent Radiol       Date:  2010-10-15       Impact factor: 2.740

5.  Long-term results of symptomatic fibroids treated with uterine artery embolization: in conjunction with MR evaluation.

Authors:  Man Deuk Kim; Hyun Seok Lee; Mee Hwa Lee; Hee Jin Kim; Jin Ho Cho; Sun Hee Cha
Journal:  Eur J Radiol       Date:  2008-12-11       Impact factor: 3.528

6.  Long-term quality of life assessment among patients undergoing uterine fibroid embolization.

Authors:  Martin Popovic; Dominik Berzaczy; Stefan Puchner; Andreas Zadina; Johannes Lammer; Robert A Bucek
Journal:  AJR Am J Roentgenol       Date:  2009-07       Impact factor: 3.959

7.  Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy--results from the randomized clinical Embolisation versus Hysterectomy (EMMY) Trial.

Authors:  Wouter J K Hehenkamp; Nicole A Volkers; Erwin Birnie; Jim A Reekers; Willem M Ankum
Journal:  Radiology       Date:  2008-01-09       Impact factor: 11.105

8.  Analysis of arterial blood vessels surrounding the myoma: relevance to myomectomy.

Authors:  Federico Discepola; David A Valenti; Caroline Reinhold; Togas Tulandi
Journal:  Obstet Gynecol       Date:  2007-12       Impact factor: 7.661

9.  Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial.

Authors:  Nicole A Volkers; Wouter J K Hehenkamp; Erwin Birnie; Willem M Ankum; Jim A Reekers
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

10.  Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy.

Authors:  Michal Mara; Jana Maskova; Zuzana Fucikova; David Kuzel; Tomas Belsan; Ondrej Sosna
Journal:  Cardiovasc Intervent Radiol       Date:  2007-10-18       Impact factor: 2.740

View more
  3 in total

1.  Increased urinary cobalt and whole blood concentrations of cadmium and lead in women with uterine leiomyomata: Findings from the ENDO Study.

Authors:  Erica B Johnstone; Germaine M Buck Louis; Patrick J Parsons; Amy J Steuerwald; Christopher D Palmer; Zhen Chen; Liping Sun; Ahmad O Hammoud; Jessie Dorais; C Matthew Peterson
Journal:  Reprod Toxicol       Date:  2014-06-30       Impact factor: 3.143

2.  Low vascularity predicts favourable outcomes in leiomyoma patients treated with uterine artery embolization.

Authors:  Yixin Tang; Chunlin Chen; Hui Duan; Ben Ma; Ping Liu
Journal:  Eur Radiol       Date:  2016-01-27       Impact factor: 5.315

3.  Prophylactic tranexamic acid to reduce blood loss and related morbidities during hysterectomy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Ahmed Abu-Zaid; Saeed Baradwan; Ehab Badghish; Rayan AlSghan; Ahmed Ghazi; Bayan Albouq; Khalid Khadawardi; Nora F AlNaim; Latifa F AlNaim; Meshael Fodaneel; Fatimah Shakir AbuAlsaud; Mohammed Ziad Jamjoom; Abdullah Ama Almubarki; Saud Owaimer Alsehaimi; Safa Alabdrabalamir; Osama Alomar; Ismail A Al-Badawi; Hany Salem
Journal:  Obstet Gynecol Sci       Date:  2022-07-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.